A novel engineered interferon-α hybrid molecule increases anticancer efficacy of doxorubicin in breast cancer chemotherapy

  • Authors:
    • Si-Jie Li
    • Chun-Shui Liu
    • Hai-Jun Li
    • Yan Li
    • Lei Zhou
    • Jin-Cheng Li
    • Yi-Chang Chen
    • Tian-Qi Su
    • De-Hai Yu
  • View Affiliations

  • Published online on: July 3, 2017     https://doi.org/10.3892/ijo.2017.4062
  • Pages: 949-958
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is the most common carcinoma among Chinese women. Interferon α (IFNα) has been used to treat various types of cancer, including breast cancer, but its antitumor activity is relative low, which significantly hinders its clinical application. In this study, we utilized a Ph.D.-12 peptide library screening system to identify a short peptide that specifically binds to MCF-7 breast cancer cells. By fusing the MCF-7 binding peptide (MBP) to the C-terminus of IFNα, we constructed an engineered IFNα-MBP fusion molecule (IMBP), and applied this novel fusion protein to the treatment of breast cancer. We found that IMBP exhibited significantly higher activity than wild-type IFNα in inhibiting cell growth and inducing cell apoptosis. Additionally, IMBP potentiated the therapeutic efficacy of doxorubicin-based breast cancer chemotherapy via the activation of cell cycle arrest and cell apoptosis pathway genes including p53, p21, CDK2, cyclin A, caspase 9, Bcl-2 and Bax. The enhanced activity of the synthetic IMBP was also associated with the activation of signal transducer and activation of transcription 1 (STAT1) pathway target genes (STAT1, IFIT1, IFITM1 and MX1). This study evaluated the potential value of the synthetic IMBP as a novel anti-breast cancer agent.
View Figures
View References

Related Articles

Journal Cover

September 2017
Volume 51 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Li, S., Liu, C., Li, H., Li, Y., Zhou, L., Li, J. ... Yu, D. (2017). A novel engineered interferon-α hybrid molecule increases anticancer efficacy of doxorubicin in breast cancer chemotherapy. International Journal of Oncology, 51, 949-958. https://doi.org/10.3892/ijo.2017.4062
MLA
Li, S., Liu, C., Li, H., Li, Y., Zhou, L., Li, J., Chen, Y., Su, T., Yu, D."A novel engineered interferon-α hybrid molecule increases anticancer efficacy of doxorubicin in breast cancer chemotherapy". International Journal of Oncology 51.3 (2017): 949-958.
Chicago
Li, S., Liu, C., Li, H., Li, Y., Zhou, L., Li, J., Chen, Y., Su, T., Yu, D."A novel engineered interferon-α hybrid molecule increases anticancer efficacy of doxorubicin in breast cancer chemotherapy". International Journal of Oncology 51, no. 3 (2017): 949-958. https://doi.org/10.3892/ijo.2017.4062